Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| I50HX003266 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| San Francisco Veterans Affairs Medical Center | FED |
Not provided
Not provided
Not provided
Not provided
The goal of this wait-list control trial is to learn if having access to a new dashboard displaying information about immunosuppressed Veterans missing vaccinations for Shingrix can improve Shingrix vaccination rates at VA facilities.
The main question[s] it aims to answer is: Will vaccination rates improve more rapidly for facilities with access to the dashboard compare to facilities without access? VA facility personnel will be granted access to the dashboard and outcomes (vaccination rates) will be measured using electronic health record data.
Assignment of the intervention will occur at the facility level. Outcomes (vaccination) will be assessed for patients cared for at each facility.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early dashboard access | Experimental | The early dashboard access arm will receive access to the Shingrix dashboard as soon as the study begins. |
|
| Wait list control arm | Other | The wait list control arm will receive no intervention for 6-9 months; after this period, this arm will also receive access to the Shingrix dashboard. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Access to Shingrix dashboard | Other | The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with at least 1 Shingrix vaccine documented, by facility | Percentage of patients with at least 1 Shingrix vaccinations documented, by facility | From enrollment until end of follow up at 18 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with at least 2 Shingrix vaccinations documented, by facility | Percentage of patients with at least 2 Shingrix vaccinations documented, by facility | From enrollment until end of follow up at 18 months. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gabriela Schmajuk, MD MS | San Francisco VA Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| San Francisco VA | San Francisco | California | 94121 | United States |
VA data is only available to VA investigators with specific permission under DUA.
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators will use a wait-list control design; clinicians from VA facilities will be randomized to receive access to the dashboard early vs. after a 6-9 month delay. The investigators will compare Shingrix vaccination rates in the two groups of facilities.
Not provided
Not provided
Not provided
Not provided
|